AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01184898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
Study NCT01184898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 8mg/m2/day IV
Study NCT02824588 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet use
Description: Used as control for time spent on computer
Study NCT03796676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03796676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 100 mg QD
Study NCT03796676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF04965842
Description: 200 mg QD
Study NCT01184898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day IV
Study NCT01184898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1000mg/m2/day IV every 24 hours for 5 days
Study NCT02660268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pathway
Description: Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
Study NCT02892864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Retraining and Virtual therapy
Description: Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
Study NCT02892864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oro-myo-functional classical rehabilitation
Description: Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
Study NCT01271023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control-to-Range Automated Insulin Management System
Description: The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
Study NCT02649361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study NCT02649361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study NCT03121612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP therapy
Study NCT00743990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ointment containing camphor, eucalyptus oil, and menthol
Description: One time use
Study NCT00743990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum jelly
Description: One time use
Study NCT02241720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Study NCT02597205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physician-facing app and patient-facing messages
Description: A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
Study NCT02769065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules
Study NCT02620085 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling
Description: blood sampling
Study NCT02971800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fluorescein injection 10%
Study NCT02190409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant
Description: This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
Study NCT00567697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
Study NCT00567697 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ranibizumab
Description: Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
Study NCT03216655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone call
Description: Investigators give a regular follow-up to participants: phone call monthly
Study NCT03216655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wechat group
Description: Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
Study NCT02018978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Triaged HIV Prevention (CTHP)
Description: 1. HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~2. Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~3. Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~4. Incentives \& Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential.
Study NCT00772187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: Single dose: 0.1-0.5 mg
Study NCT00772187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal analgesia (morphine)
Description: 0.1-0.5 mg of morphine
Study NCT00772187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia (fentanyl)
Description: general anesthesia alone
Study NCT02862925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Scalp Stimulation
Description: During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention.
Study NCT00699712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP (Chimeric natriuretic peptide)
Description: Infusion of CDNP at two of four doses
Study NCT04291742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cognitive vs software
Description: cognitive vs software
Study NCT03588013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: 4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ \< -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.
Study NCT03588013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional education
Description: 4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ \< -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.
Study NCT03588013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food
Description: If child remains WHZ \< -2 despite nutritional education then will be managed according to Pakistan's Community Management of Acute Malnutrition protocol. This will include provision of ready to use therapeutic food (RUTF) to the child at home with close follow up. Utilization of the RUTF will be monitored closely by bi-weekly home visits.
Study NCT03588013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy with biopsy
Description: If child remains at WHZ \< -2 despite educational and dietary interventions, then will undergo medical evaluation for assessment of need for more advanced workup of malnutrition, including UGI endoscopy at AKUH. Results of the advanced work up, including the UGI endoscopy, will guide future management of these children.
Study NCT00002575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT03121612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP therapy
Study NCT04811339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable
Description: Pepto bismol (bismuth subsalicylate)
Study NCT04811339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable
Description: Pepto bismol (bismuth subsalicylate)
Study NCT00002575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Study NCT02089087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Single dose at varying dosage levels depending on treatment assignment
Study NCT02089087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02287259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Study NCT02287259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium
Study NCT03476655 — intervention group
Intervention type: DRUG
Intervention: Ibrutinib
Description: No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
Study NCT04735159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCS implanted with Precision SpectraTM
Description: Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
Study NCT03046992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH25448
Description: * Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448
Study NCT03292471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
Study NCT01612078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 200mg/tab 2tablets, po, three times a week
Study NCT01612078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg/tab, po, three times a week.
Study NCT04811339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet without BSS
Description: Placebo Tablet made by P \& G to contain everything except active ingredient ( BSS)
Study NCT04228354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
Study NCT03201536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Suture
Description: Sutures
Study NCT03201536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip3
Description: wound closure device
Study NCT00483704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Telcagepant 140 mg
Description: Telcagepant 140 mg tablets
Study NCT00483704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant 140 mg
Description: Telcagepant 140 mg tablets
Study NCT00483704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcagepant 280 mg
Description: Telcagepant 280 mg tablets
Study NCT00483704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT03237780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03237780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT03237780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03237780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography with Contrast
Description: Undergo CT scan
Study NCT03237780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study NCT02005627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazax
Description: The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
Study NCT02005627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazax Placebo
Description: This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
Study NCT05015543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Training Program
Description: One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.
Study NCT03121573 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
Study NCT02397434 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant EBRT
Description: Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
Study NCT01225289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: 25000 IU/day (one capsule per day) Vitamin A for 6 months
Study NCT01225289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day for six months
Study NCT04875689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A (Experimental
Description: Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~* Joint mobilizations
Study NCT04875689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Group B (Control)
Description: 1. Participants of this group will receive only conventional therapy which will include;~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~* Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~* Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide).
Study NCT03602833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound 451238
Description: Each patient will receive compound 451238 until disease progression unacceptable toxicities.
Study NCT01110668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT02552888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release sodium nitrite
Description: Immediate release sodium nitrite 40 mg by mouth twice per day
Study NCT02552888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Isoquercetin 225 mg by mouth once per day
Study NCT02552888 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebos
Description: placebos
Study NCT00553358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Small molecule receptor tyrosine kinase inhibitor
Study NCT00553358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Therapeutic Monoclonal Antibody
Study NCT00553358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Therapeutic Monoclonal Antibody
Study NCT00553358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: antimicrotubule agent
Study NCT00553358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: antimicrotubule agent
Study NCT02769065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet
Study NCT02769065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet
Study NCT02769065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching capsules
Study NCT02769065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching capsules
Study NCT02769065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet
Study NCT01708720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Study NCT01708720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabin-IPV
Study NCT01708720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvanted Sabin-IPV
Study NCT05459194 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RP - TA
Description: randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
Study NCT05459194 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RP - TA
Description: randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
Study NCT03881891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-app intervention arm
Description: The intervention includes implementation and evaluation of the effectiveness of a mobile phone-based text messaging system (FollowApp.Care) to collect patients' assessments of their post-op symptoms (pain intensity) and to use that data to improve their quality of care (pain experience) in the dental office setting
Study NCT02811380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP CVC
Description: BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
Study NCT02811380 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Uncoated Standard CVC
Description: Standard CVC catheterization for venous access during and after elective large surgery